Children's International Polyposis (CHIP) study : a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis by Burke, Carol A et al.
© 2017 Burke et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Clinical and Experimental Gastroenterology 2017:10 177–185
Clinical and Experimental Gastroenterology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
177
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CEG.S121841
Children’s International Polyposis (CHIP) study: 
a randomized, double-blind, placebo-controlled 
study of celecoxib in children with familial 
adenomatous polyposis
Carol A Burke1 
Robin Phillips2 
Manuela F Berger3 
Chunming Li3 
Margaret Noyes Essex4 
Dinu Iorga3
Patrick M Lynch5
1Department of Gastroenterology 
and Hepatology, Cleveland Clinic, 
Cleveland, OH, USA; 2Department 
of Surgery, St Mark’s Hospital and 
Academic Institute, Middlesex, UK; 
3Global Clinical Affairs, 4Global 
Medical Affairs, Pfizer Inc., New York, 
NY, 5Department of Gastroenterology, 
Hepatology and Nutrition, The 
University of Texas MD Anderson 
Cancer Center, Houston, TX, USA
Objective: To evaluate the efficacy and safety of celecoxib versus placebo in the prevention 
and treatment of colorectal polyposis in children with familial adenomatous polyposis (FAP).
Methods: In this Phase III, double-blind, randomized, placebo-controlled, multicenter trial 
patients aged 10–17 years with FAP were randomized to celecoxib (16 mg/kg/day) or placebo 
for up to 5 years. Patients underwent annual assessments, including colonoscopies, to detect the 
time from randomization to the earliest occurrence of ≥20 polyps (>2 mm in size) or colorectal 
malignancy. The study was terminated early due to low rate of observed endpoints combined 
with a lower than expected enrollment rate. Descriptive results are provided.
Results: Of 106 randomized patients, 55 were treated with celecoxib (mean age 12.6 years; 
52.7% female) and 51 were given placebo (mean age 12.2 years; 54.9% female). Disease pro-
gression (≥20 polyps, >2 mm in size) was observed in seven (12.7%) and 13 (25.5%) patients, 
respectively. The median time to disease progression was 2.1 years in the celecoxib group and 
1.1 years for placebo. No patient developed colorectal cancer. The rate of adverse events (AEs) 
was similar in both groups (75.5% and 72.9%, respectively). Three patients in the celecoxib 
group (none in the placebo group) experienced serious AEs.
Conclusion: In children with FAP, celecoxib was a well-tolerated treatment that was associated 
with a lower rate of colorectal polyposis and a longer time to disease progression compared 
with placebo. Due to the low rate of observed endpoints, the long-term impact of these results 
could not be ascertained.
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Introduction
Familial adenomatous polyposis (FAP) is an autosomal dominant disease occurring 
in ~1 in 13,000 births.1 FAP is caused by a germline mutation in the adenomatous 
polyposis coli (APC) gene. A recent study reported that the mean age of onset of 
colorectal polyps in children with FAP was 13.4 years and 60% of children harbored 
>50 polyps at the time of diagnosis.2 If left untreated, polyposis invariably progresses, 
with a near certainty of patients developing colorectal cancer by the fifth decade of 
life if colectomy is not performed.3
The standard management of FAP is by surgical intervention and involves prophy-
lactic total colectomy and ileorectal anastomosis (IRA), or proctocolectomy and ileal 
pouch anal anastomosis (IPAA) with postoperative endoscopic surveillance and polyp-
ectomy. Neither the timing of this surgery nor the procedure itself has been standardized 
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in pediatric patients with FAP.4 Factors such as the presence 
of symptoms, polyp burden, psychosocial implications, and 
physical maturity, to name a few, must be considered before 
the decision to carry out this surgery is made.
Although surgery is effective in the prevention of colon 
cancer, it comes with a risk of mortality and postoperative 
complications.5,6 Moreover, surgery does not prevent the 
development of rectal or ileal pouch polyposis. In one long-
term follow-up study, 7/34 (21%) children treated with an 
IRA required proctectomy for either rectal cancer or advanced 
rectal polyposis, and 2/7 (29%) FAP patients treated with 
IPAA had postoperative pouch polyposis within one decade 
of surgery.7 Another study in patients who had undergone 
IPAA for FAP 10 years previously found that 42% of patients 
had developed adenoma of the pouch.8
The use of chemoprevention for FAP has been reviewed 
previously.9 The goal of this therapy is to prevent, or lead 
to the regression of, colorectal adenomas and to prevent 
postoperative recurrence. If shown to be well tolerated and 
associated with long-term effectiveness in children, chemo-
prevention may delay the timing of, or alter the approach to, 
surgical intervention and may decrease the need for endo-
scopic intervention.
Following observations that gene expression of cyclo-
oxygenase-2 (COX-2) is upregulated in many premalignant 
lesions such as colorectal adenomas,10,11 COX-2 selective 
inhibition has been considered as a potential chemopreven-
tive strategy for treating FAP. A short-duration, randomized, 
placebo-controlled trial of celecoxib in children with FAP 
demonstrated a significant reduction in colorectal polyp 
burden compared with placebo;4 however, due to the short 
duration of that study, conclusions cannot be drawn on long-
term efficacy and safety of celecoxib for FAP.
The objective of the present study was to assess the effi-
cacy and safety of celecoxib versus placebo in children with 
FAP over a 5-year treatment duration.
Methods
Trial design
This was a Phase III, double-blind, randomized, placebo-
controlled, multicenter trial in children with FAP. The study was 
designed to compare efficacy and safety of celecoxib versus 
placebo for the treatment of colorectal polyposis over a 5-year 
treatment period. The protocol and informed consent docu-
ments were reviewed and approved by an Institutional Review 
Board or Independent Ethics Committee at each participating 
study center (see the “Supplementary materials” and “Acknowl-
edgments” sections), written assent was obtained from patients 
and written informed consent was obtained from parents prior 
to performing any study-related procedures. The trial was 
performed in accordance with the protocol, the International 
Conference on Harmonisation Good Clinical Practice guide-
lines, and applicable local regulatory requirements and laws.
The multinational clinical study was conducted at 18 
centers located in 13 countries.
Participants and interventions
A total of 200 eligible patients with FAP from multiple inter-
national centers were to be randomly assigned in a 1:1 ratio 
to receive either celecoxib (up to 16 mg/kg/day) or matching 
placebo for up to 5 years. Celecoxib was administered based 
on patients’ weight as follows: body weight 25.0–37.5 kg, 
dosage 200 mg BID; 37.6–50.0 kg, 300 mg BID; >50.0 kg, 
400 mg BID. The dose was adjusted based on body weight 
at return visits according to the protocol. 
A central Internet/telephone system was used to assign 
each patient a randomization number. Randomization was 
carried out in block size of 4 and was stratified by center, age 
(≥12 vs <12 years), and FAP phenotype (negative vs positive).
The study comprised patients aged 10–17 years (inclu-
sive). Patients were required to have either a deleterious APC 
gene mutation, based on central genetic testing, including a 
non-attenuated genotype or an attenuated genotype and a 
personal history of colorectal adenomas plus a first-degree 
relative with colectomy, colorectal cancer, or >100 adenomas 
by the age of 40; or if no gene mutation was detected in the 
family, a personal history of >2 adenomas and a parent with 
the FAP phenotype, as stated earlier. Patients were required 
to have <20 polyps of >2 mm at baseline colonoscopy that 
had to be completely excised, to render the colon free of 
polyps >2 mm in size before administration of study drug.
Other inclusion criteria were negative pregnancy test 
and willingness to use effective birth control among female 
patients, abstention from use of other non-steroidal anti-inflam-
matory drugs (NSAIDs), intact colon, and normal blood tests.
Key exclusion criteria were sensitivity to COX-2 selective 
NSAIDs, recent use of NSAIDs or oral adrenocorticosteroid, 
the need for concurrent use of fluconazole or lithium, and 
active peptic ulcer.
All patients underwent baseline colonoscopy under anes-
thesia, according to standard local practice, with complete 
excision of all polyps >2 mm in size in eligible patients. At 
a Month 6 visit, patients underwent physical and labora-
tory examination and safety monitoring. At annual visits, 
colonoscopies were performed to assess the number and 
size of colorectal polyps, with complete excision for all 
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patients who developed <20 colorectal polyps (>2 mm in 
size). Histologic assessment of biopsied polyps was collected 
if available. Telephone monitoring was carried out at least 
every 3 months.
Study endpoints
The primary endpoint was the time to disease progression, 
defined as the time from randomization to the earliest occur-
rence of the following events:
1. appearance of ≥20 polyps (>2 mm in size) at any colo-
noscopy during the study;
2. diagnosis of colorectal malignancy. 
Secondary endpoints included
1. the time from randomization to treatment failure, where 
treatment failure was defined as:
a. earliest occurrence of ≥20 polyps (>2 mm in size) at 
colonoscopy,
b. colorectal malignancy, or
c. treatment-related dropout (insuff icient clinical 
response, disease progression, death, adverse events 
[AEs], treatment-related laboratory abnormalities, 
patient no longer willing to participate in the study, 
and other reasons related to treatment);
2. the weighted total number of colorectal polyps (>2 mm in 
size) diagnosed over Years 1–5 cumulatively, which was 
calculated as the sum of polyps over the 5 years divided 
by the number of colonoscopies the patient had during 
the study;
3. the polyp burden, defined as the sum of the largest 
diameters of all polyps (>2 mm in size) detected at each 
colonoscopy over the 5 years, divided by the number of 
colonoscopies the patient had during the study.
Safety endpoints were based on investigator-reported 
AEs, serious adverse events (SAEs), laboratory measure-
ments, and physical examinations. AEs were coded accord-
ing to criteria from the Medical Dictionary for Regulatory 
Activities, version 16.1.
Data analysis
The sample size calculation for this study was originally 
based on the primary endpoint and the assumption that the 
hazard rates (HRs) for patients treated with placebo and 
celecoxib were 0.37942 and 0.24079, respectively. A total 
of 152 events would have been needed to show that the cele-
coxib group was superior to the placebo group (HR=1.576) 
at a significance level of 0.05 and with 80% power. Interim 
efficacy analyses were planned at increments of ~30 primary 
endpoint events.
In November 2012, the Data Safety Monitoring Board 
recommended that the trial be stopped if the 6-month enroll-
ment rate was <10 patients, if the pooled observed HR was 
<0.16 events/person-year, or if there were any safety con-
cerns. The first two conditions were met and the trial was 
terminated on October 31, 2013.
Due to early study termination, only descriptive statistics 
were analyzed and presented. The interim analysis that was 
originally planned was not conducted.
Endpoints were assessed in the intent-to-treat (ITT) 
population, consisting of all patients who were randomized 
(with study drug assignment designated according to initial 
randomization), regardless of whether patients received any 
study drug or received a different drug from that to which 
they were randomized.
Safety was assessed in all patients who received at 
least one dose of study medication, with treatment assign-
ments designated according to the actual study treatment 
received.
Results
Patient disposition
Patients were recruited between September 2006 and October 
2013 from centers in Belgium, Czech Republic, Hong Kong, 
Hungary, Israel, Italy, Slovakia, South Africa, Spain, Sweden, 
Ukraine, the UK, and the US. Of 305 patients screened for 
eligibility, 106 were randomized into the study: 55 to the 
celecoxib group and 51 to the placebo group (ITT popula-
tion, Figure 1). Of those randomized, 53 (96.4%) patients 
received treatment with celecoxib and 48 (94.1%) patients 
received placebo (safety population); 64 patients were from 
the US, 35 were from Europe, and 7 were from Hong Kong, 
Israel, and South Africa.
Out of the 106 randomized patients, 85 were still active in 
2013, when the study was terminated. The other 21 patients 
were discontinued prior to 2013, as follows: 2 in 2009, 3 
in 2010, 5 in 2011, and 11 in 2012. Discontinuations were 
considered related to study drug treatment (treatment fail-
ure or related AE resulting in discontinuation) occurred for 
nine (16.4%) patients in the celecoxib group (three patients 
for AEs, six patients for treatment failure) and 11 (21.6%) 
patients in the placebo group (all due to treatment failure). 
Compliance with medication, assessed by medication counts 
and patient diary, was similar between the groups.
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Baseline characteristics
The two arms of the study were balanced with respect to 
baseline characteristics; most patients were aged ~12 years 
and were white, and there were slightly more females than 
males in both groups (Table 1).
Ongoing coexisting medical conditions were reported in 
37 (67.3%) patients in the celecoxib group and 28 (54.9%) 
in the placebo group. The most common of these were ner-
vous system disorders (16 patients in the celecoxib group 
vs 15 in the placebo group), immune system disorders (13 
vs 9, respectively), and psychiatric disorders (11 vs 10, 
respectively). The majority of patients’ mutation location 
was exon 15 (n=65), with equal numbers (n=12) having 
mutations at exons 10–14 and exons 5–8, and fewer at exon 
9 (n=4) and exons 1–4 (n=2). An additional 11 patients had 
other mutations.
Study endpoints
Among those who were treated (safety population), the 
median duration of treatment was 23.0 months for patients 
in the celecoxib group and 25.5 months for those in the 
placebo group. In the ITT population, 20 patients met the 
primary endpoint (development of ≥20 polyps >2 mm in 
size) during the study, seven (12.7%) of 55 patients in the 
celecoxib group and 13 (25.5%) of 51 in the placebo group. 
The median time to disease progression was 2.1 years in 
the celecoxib group and 1.1 years for placebo. None of the 
patients developed a colorectal malignancy. The cumulative 
rate of patients reaching the primary endpoint over the 5-year 
follow-up period (appearance of ≥20 polyps that are >2 mm 
in size) is shown in Figure 2.
A similar proportion of patients met the secondary end-
point (14 in each group), which compared the time from 
Screened
N=305
Randomized
N=106
Placebo
(ITT population)
n=51
Treated
(safety population)
n=48
Treated
(safety population)
n=48
Completed 5 years
n=7
Completed 5 years
n=4
Celecoxib
(ITT population)
n=55Completed: 7
Discontinued: 44
   Before treatment: 3
      Terminated by sponsor: 3
   After treatment: 41
      Adverse event: 0
      Lack of perceived efficacy: 11
      Lost to follow-up: 1
      Consent withdrawn: 1
      Other*: 0
      Terminated by sponsor: 28
Completed: 4
Discontinued: 51
   Before treatment: 2
      Terminated by sponsor: 2
    After treatment: 49
      Adverse event: 3
      Lack of perceived efficacy: 6
      Lost to follow-up: 1
      Consent withdrawn: 5
      Other*: 2
      Terminated by sponsor: 32
Figure 1 Patient disposition.
Note: *Includes “Does not meet entrance criteria” and “Protocol violation”.
Abbreviation: ITT, intent-to-treat.
Table 1 Baseline patient characteristics (ITT population)
Celecoxib (n=55) Placebo (n=51)
Female Male Total Female Male Total
Sex, n (%) 29 (52.7) 26 (47.3) 55 28 (54.9) 23 (45.1) 51
Age
Mean (SD)
Range
12.4 (2.3) 
10–17
12.8 (2.0) 
10–17
12.6 (2.2) 
10–17
12.0 (1.7) 
10–15
12.4 (2.0) 
10–17
12.2 (1.8) 
10–17
Race, n (%)
White
Black
Asian
Other
26 (89.7)
1 (3.4)
0
2 (6.9)
20 (76.9)
1 (3.8)
1 (3.8)
4 (15.4)
46 (83.6)
2 (3.6)
1 (1.8)
6 (10.9)
21 (75.0)
0
0
7 (25.0)
19 (82.6)
2 (8.7)
1 (4.3)
1 (4.3)
40 (78.4)
2 (3.9)
1 (2.0)
8 (15.7)
Abbreviations: ITT, intent-to-treat; SD, standard deviation.
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randomization to treatment failure (including development 
of ≥20 polyps [>2 mm in size], diagnosis of colorectal malig-
nancy, and treatment-related dropout). The median time to 
treatment failure was 2.0 years in the celecoxib group and 
1.1 years for placebo. Treatment-related dropout occurred in 
14 (25.5%) patients in the celecoxib group and 12 (23.5%) 
patients in the placebo group.
The weighted total number of colorectal polyps (>2 mm 
in size) diagnosed over Years 1–5 cumulatively is shown 
in Table 2. The mean (standard deviation) polyp burden in 
the celecoxib and placebo groups was 4.1 (1.68) and 4.3 
(1.61) mm, respectively.
Safety
The number of AEs and treatment-related AEs were similar 
in the two treatment groups (Table 3). Of the six patients 
in the celecoxib group who discontinued treatment due to 
AEs, three were considered to have had treatment-related 
AEs. The most common AEs, occurring in >10% patients 
in a group, were headache, abdominal pain, vomiting, and 
nausea (Table 4).
Three patients in the celecoxib group experienced SAEs 
during the treatment period (depression, pneumonia, and peri-
orbital cellulitis secondary to sinusitis); none were considered 
to be related to the study drug. No patients in the placebo 
group experienced SAEs. One patient in the celecoxib treat-
ment group reported SAEs after completion of treatment that 
were considered by the investigator and sponsor as related 
to the study drug treatment. These were Escherichia sepsis, 
maternal exposure, and delivery of a premature baby. Despite 
taking oral contraceptives, this patient became pregnant dur-
ing the study and gave birth, prematurely, ~9 months after 
study visit 3 (Year 1). Treatment with the study drug had 
been discontinued ~1 month previously. The infant died 11 
days later.
The incidence of specific laboratory abnormalities and 
shifts of baseline values from normal levels was comparable 
between the treatment groups.
Discussion
This Phase III randomized, double-blind, placebo-controlled 
celecoxib trial is one of the largest studies to assess the effi-
cacy and safety of chemoprevention in children with FAP. 
The study endpoint, progression of polyposis to ≥20 polyps 
>2 mm in size in 1 year, was determined to be of clinical 
significance and of prudent safety by a consensus of inves-
tigators before the study was incepted. Fewer children with 
FAP who received 16 mg/kg/day doses of celecoxib reached 
the primary endpoint than patients who received placebo. 
Furthermore, celecoxib was associated with a slower rate of 
disease progression compared with placebo, with the time 
to disease progression being on average 1 year longer for 
patients who received celecoxib than those who received pla-
cebo. No patients in either group developed colorectal cancer 
during the study and celecoxib was generally well tolerated. 
However, the long-term impact of celecoxib on colorectal 
100 Celecoxib Placebo
C
um
ul
at
iv
e 
ev
en
t r
at
e 
(%
)
90
80
70
60
50
40
30
20
10
0
0 1 2 3
Time (years)
4 5 6
Figure 2 Time to disease progression (ITT population).
Note: Event defined as the appearance of >20 polyps that are >2 mm in size or 
diagnosis of colorectal malignancy. 
Abbreviation: ITT, intent-to-treat.
Table 2 Total number of colorectal polyps (>2 mm in size) 
detected at annual colonoscopies findings (ITT population)
Celecoxib
(n=55)
Placebo
(n=51)
Year 1 
N
Mean (SD)
Median
27
3.0 (2.68)
2.0
30
8.1 (7.32)
6.0
Year 2
N
Mean (SD)
Median
21
8.8 (6.63)
6.0
25
13.7 (10.51)
11.0
Year 3
N
Mean (SD)
Median
16
13.4 (11.31)
10.0
14
22.3 (11.74)
20.0
Year 4
N
Mean (SD)
Median
8
18.6 (17.65)
11.5
7
36.4 (22.50)
32.0
Year 5
N
Mean (SD)
Median
2
30.5 (21.92)
30.5
2
46.5 (34.65)
46.5
Years 1–5 cumulatively
N
Mean (SD)
Median
33
4.3 (3.58)
3.0
36
8.6 (7.12)
7.0
Abbreviations: ITT, intent-to-treat; SD, standard deviation.
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polyposis in children with FAP is unknown, because the study 
was terminated early due to the low occurrence of disease 
progression observed over the course of the study.
The results of this study, while limited by early termination, 
are valuable to clinicians and patients. Delaying disease progres-
sion in FAP is important as it affords a potential opportunity 
for children and parents to delay the timing for colectomy. 
Elective surgery is usually undertaken at an age of 16–20 
years;12 however, the optimal timing has not been determined.4 
Decisions about the timing of surgery should take into account 
psychosocial factors so as to minimize disruption to the child’s 
personal development. In some cases, delaying surgery so that 
it causes the least disruption to educational or work activities 
is necessary.12 After IPAA, there is usually a permanent effect 
on the patient’s bowel function, and in some cases sexual func-
tion can be altered.3 It is therefore important that patients are 
educated in advance about the possible quality of life changes 
post-surgery so that their expectations can be managed.3
Although the use of COX-2 selective and nonselective 
NSAIDs as potential adjunctive therapies for patients with 
FAP who have undergone prophylactic surgery has been 
recommended,13 the application of these treatments in a 
pediatric population has not been rigorously tested. The 
Children’s International Polyposis (CHIP) trial was designed 
to provide long-term efficacy and safety data on celecoxib 
for the reduction of the number of polyps in children with 
FAP. The ages of patients in this trial were representative of 
the age at which screening is carried out in children with 
polyposis.14 The study of chemoprevention in children with 
FAP is important for clinical practice, where early interven-
tion may lead to slower progression of polyposis, which may 
translate to improved outcomes such as a delay in surgery or 
fewer polypectomies. Earlier studies of chemoprevention in 
FAP with NSAIDs focused predominantly on adult popula-
tions15–18 and found them to be useful adjuncts to endoscopy.
Previous trials4,15 and cohort studies19 have provided some 
evidence for the efficacy of celecoxib in FAP, but they were 
limited by both small sample size and relatively short dura-
tion. In a Phase I dose-escalation study in 18 children, three 
cohorts of patients received celecoxib at sequential doses of 
4, 8, or 16 mg/kg/day, or placebo for 3 months. The number 
of polyps increased in the placebo and 4 mg/kg celecoxib 
groups by a median (range) of 17.5 (−5 to 63) and 5.5 (2–17) 
polyps, respectively. In patients treated with celecoxib at 8 
and 16 mg/kg doses, there was a median decrease in the 
number of polyps by −7.0 (−2 to −16) and −17.5 (−2 to 
−48), respectively (p=0.011), confirming a dose-dependent 
response with celecoxib in FAP.4
The chemopreventive attributes of celecoxib have also 
been evaluated in a short-term study of adults.15 In this trial, 
a 6-month treatment period was selected, based on previous 
studies with sulindac, an NSAID that acts on both COX-1 
and COX-2 enzymes and has also been shown to reduce the 
number and size of colorectal polyps.16,17 In total, 77 patients 
with FAP received 400 mg celecoxib twice daily or placebo. 
In the active treatment group, there was a significant 28% 
Table 4 AEs occurring in ≥10% of patients per group (safety 
population)
Celecoxib, n (%) 
(n=53)
Placebo, n (%) 
(n=48)
Headache 16 (30.2) 14 (29.2)
Abdominal pain 9 (17.0) 10 (20.8)
Vomiting 9 (17.0) 9 (18.8)
Nausea 8 (15.1) 8 (16.7)
Cough 8 (15.1) 6 (12.5)
Abdominal discomfort 9 (17.0) 4 (8.3)
Oropharyngeal pain 6 (11.3) 5 (10.4)
Diarrhea 6 (11.3) 4 (8.3)
Fatigue 6 (11.3) 4 (8.3)
Nasopharyngitis 6 (11.3) 4 (8.3)
Upper respiratory tract infection 4 (7.5) 9 (18.8)
Influenza 6 (11.3) 1 (2.1)
Seasonal allergy 2 (3.8) 5 (10.4)
Abbreviation: AEs, adverse events. 
Table 3 Patients with AEs (safety population)*
Celecoxib, n (%) (n=53) Placebo, n (%) (n=48)
All causes Treatment related All causes Treatment related
Total AEs observed 270 43 226 43
Patients with any AE 40 (75.5) 18 (34.0) 35 (72.9) 15 (31.3)
Patients with serious AEs 3 (5.7) 0 0 0
Patients with severe AEs 5 (9.4) 1 (1.9) 3 (6.3) 0
Patients permanently discontinued study due to AEs 3 (5.7) 0 0 0
Patients permanently discontinued treatment due to AEs 6 (11.3) 4 (7.5) 1 (2.1) 1 (2.1)
Patients with dose reduction or temporary discontinuation 
due to AEs
19 (35.8) 4 (7.5) 12 (25.0) 2 (4.2)
Notes: *Includes data up to 30 days after last dose of study drug. Except for the number of AEs, patients were counted only once per treatment in each row. Relationship 
of SAEs is displayed according to the investigator’s assessment.
Abbreviations: AE, adverse event; SAE, serious adverse event.
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reduction in the mean number of colorectal polyps (p=0.003) 
and a 31% reduction in polyp burden (p=0.001), compared 
with placebo.15
Although NSAIDs are very commonly used drugs, long-
term use at relatively high doses has been associated with 
increases in gastrointestinal and cardiovascular risk.20 As a 
result, there is a need to assess the relative long-term risks and 
benefits of celecoxib in different clinical settings, including 
patients with or without vascular disease and in those with 
adenomas;21 few studies have investigated the long-term 
effects of NSAIDs in children. The Adenoma Prevention with 
Celecoxib trial examined the efficacy and safety of celecoxib 
for preventing sporadic colorectal adenoma in >2,000 adults 
who were at high risk for colorectal cancer. Celecoxib was 
an effective agent in the trial but could not be recommended 
because of potential cardiovascular AEs.18 A 5-year follow-up 
of the trial noted that cardiovascular AEs were particularly 
associated with a history of atherosclerotic heart disease.22 
It is not clear whether there are specific populations who 
may benefit from adenoma prevention with a COX-2 selec-
tive NSAID.
Because FAP is incurable and associated with substantial 
morbidity and tumor-related mortality, a safe and effective 
agent to manage the disease is desperately needed. Under-
standing of the utility of chemoprevention in the colorectum of 
patients with FAP has progressed over the last 40 years, due to 
several studies that have shown a short-term benefit of NSAIDs 
on polyp burden.4,5–17 Despite this, the search continues for a 
chemopreventive agent that is both effective and nontoxic. This 
study, despite being terminated prematurely, determined that 
at a median of 2 years of treatment there was a 50% reduc-
tion in the number of pediatric patients who met the primary 
outcome of disease progression in the celecoxib arm compared 
with patients in the placebo arm. Although it was not possible 
to confirm the statistical significance of celecoxib’s efficacy, 
the safety results indicate that celecoxib was a well-tolerated 
treatment in this population of children with FAP.
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